The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.

Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...

Community-acquired pneumonia is a major global health challenge that disproportionately affects vulnerable populations, including older people, immunocompromised people, those with chronic conditions, ...